Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease).

Inclusion Criteria:Age ≥ 18 yearsAbility to provide written informed consent and HIPAA authorizationPatients with inoperable or unresectable stage III NSCLC who are planning to receive concurrent CRT followed by consolidation DurvalumabPatients with inoperable or unresectable stage III NSCLC who have previously received concurrent CRT if they enroll prior to receiving 1st cycle of Durvalumab are eligible.Must have viable tissue for ctDNA profiling, (fresh or archived tissue)Exclusion Criteria:Patient unwilling to provide tissue and blood samples for ctDNA testing.Patient has contraindications to treatment with concurrent CRT and/or consolidation Durvalumab.Patients with any other active cancer; excluding squamous cell or basal cell cancer.